Evidence map›Paper›PMID 38835145›Full record

ArticleBiomolecules & therapeutics2024

Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model.

Bo Min Kang, Dongbum Kim, Jinsoo Kim, Kyeongbin Baek, Sangkyu Park, Ha-Eun Shin, Myeong-Heon Lee, Minyoung Kim, Suyeon Kim, Younghee Lee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo Min KangDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Dongbum KimInstitute of Medical Science, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Jinsoo KimInstitute of Medical Science, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Kyeongbin BaekDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Sangkyu ParkDepartment of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, Republic of Korea.
Ha-Eun ShinDepartment of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, Republic of Korea.
Myeong-Heon LeeDepartment of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, Republic of Korea.
Minyoung KimDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Suyeon KimDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Younghee LeeDepartment of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, Republic of Korea.
Hyung-Joo KwonDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paxlovid is the first approved oral treatment for coronavirus disease 2019 and includes nirmatrelvir, a protease inhibitor targeting the main protease (M

Indexed as

COVID-19Drug resistanceLong-term infection modelNirmatrelvirSARS-CoV-2

Identifiers

PMID38835145
PMCPMC11214963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.